The case for & against
Bull & Bear analysis
Bearish
Profound Medical Inc. (NASDAQ: PROF) is an innovative company specializing in ultrasound and MRI-guided solutions for the treatment of prostate disease. The company has positioned itself as a frontrunner in the healthcare sector, focusing on incision-free therapies through its proprietary TULSA technology. As part of a significant thematic trend towards minimally invasive medical technologies, Profound aims to transform patient treatment pathways and improve clinical outcomes, making it essential in the urological treatment landscape.
Bull says
- ↑104% YoY revenue growth to $5.3M in Q1'26; $25M full-year guide (56% increase)
- ↑TULSA delivered superior outcomes in CAPTEN trial; Humana reimbursement added
- ↑Cash reserves of $50.3M as of Q1'26 fuel expansion and operations
- ↑Gross margin improved to 72% in Q1'26 driven by higher-margin equipment
- ↑Upcoming TULSA AI software launch to streamline BPH procedures
- ↑Plan to scale to 200 sites at 50 cases/year underpins market penetration
Bear says
- ↓Q1 net loss of $7M (-$0.19/share) vs. $10.7M loss year-ago highlights unprofitability
- ↓Operating expenses of $11.8M in Q1 remain high relative to revenues
- ↓Negative profitability metrics signal potential cash flow pressure
- ↓Competitive incumbents and slow adoption could hinder TULSA uptake
- ↓Elevated short interest and negative sentiment may cap stock performance
- ↓Downward analyst revisions reflect cautious near-term outlook
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-01-2026bullish
Transcript signals
Bull points
- our clinical story continues to be strong and clear in terms of both clinical benefits of Tulsa and the experience of the patient. FALSA's precision, flexibility, and resulting TAM in prostate disease is unmatched by any competing technology.
- The clinical data from CAPTIN will be presented at urological conferences every year for the next 10 years as it is the most comprehensive trial done yet and the first level 1 data for prostate care.
- believe that as more data is published, that it will lead to recommendations from relevant cancer societies, which will most likely lead to guidelines that will effectively require that patients be made aware of Tulsa as an option.
Bear points
- Total operating expenses in the 2025 first quarter, which consists of R&D and SG&A expenses, were $13 million compared with $8.7 million in the first quarter of 2024.
- Overall, the company recorded a first quarter 2025 net loss of $10.7 million or $0.36 per common share compared to a net loss of $6.6 million or $0.27 per common share for the same three-month period in 2024.
Read full transcript analysis ›